3 results about "Alcoholic fatty liver" patented technology

The invention provides a dual agonist peptide of an adiponectin receptor-1 and receptor-2 for treating NAFLD and liver fibrosis, and a pharmaceutical composition comprising the same. The dual agonistpeptide comprises amino acid sequence: P-X2-L-Y-X5-F-X7, wherein at least one of X2, X5 and X7 is unnatural amino acid, P is proline, L is leucine, and Y is tyrosine. The dual agonist peptide of adiponectin receptor-1 and adiponectin receptor-2 in the invention can effectively treat NAFLD and liver fibrosis, and has the advantages of good biological activity, good stability and easy magnificationproduction, low cost, low toxicity, large safety window, and small dosage.

The invention provides application of trilobatin in preparation of a medicine for preventing and/or treating non-alcoholic fatty liver disease. The trilobatin is researched and found for the first time to be capable of improving blood glucose metabolism disorder, abnormal blood lipid metabolism, liver function impairment, liver inflammatory response, liver injury, liver fatty degeneration and lipid deposition caused by the non-alcoholic fatty liver disease, and the trilobatin and the derivative thereof have a good treatment effect on the non-alcoholic fatty liver disease. The invention provides a novel and efficient natural medicine source for treating the non-alcoholic fatty liver disease.

The present invention relates to new methods for assessing NAFLD and NAH in a patient, combining measurement of serum markers through a logistic function.